Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 1,852 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Deformity; Skin Clear all

Conditions: Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
Interventions: Pegtarviliase IV, Pegtarviliase SC; Drug
Lead sponsor: Aeglea Biotherapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neonatal Jaundice, Hyperbilirubinemia
Interventions: Stanate (TM) [stannsoporfin, tin-mesoporphyrin]; Drug
Lead sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company; Industry
Eligibility: 12 Hours to 1 Week
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Chronic Hemolytic Disorders
Interventions: Sodium Nitrite Cream; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: AZD5055, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
Interventions: CYH33; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Dallas, Texas • Houston, Texas

Conditions: Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions: PF-06952229, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: Recurrent or Tophaceous Gout
Interventions: Control, Gout Disease Management Program; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 80 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: All KPNC Facilities, California

Conditions: Atopic Dermatitis
Interventions: Tilrekimig, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more

Conditions: Gastrointestinal, Colic
Interventions: Lactobacillus reuteri, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 3 Weeks to 3 Months
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atopic Dermatitis
Interventions: Skin tape strips; Other
Lead sponsor: National Jewish Health; Other
Eligibility: 4 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cancer
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2015
U.S. locations: 1
States / cities: Duarte, California

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more

Conditions: Adenomatous Polyp, Crohn Disease, Familial Adenomatous Polyposis, Hereditary Intestinal Polyposis Syndrome, Recurrent Colon Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer
Interventions: therapeutic laparoscopic surgery; Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer
Interventions: acyclovir, acyclovir sodium, valacyclovir; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 6
States / cities: Duarte, California • Stanford, California • Omaha, Nebraska + 3 more

Conditions: Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions: Cream, 0.1% Uracil Cream; Drug
Lead sponsor: Nanometics (d.b.a. PHD Biosciences); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more

Conditions: Oral Dysplasia, Leukoplakia Oral, Leukoplakia
Interventions: Imiquimod (topical use); Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: PTR-01; Drug
Lead sponsor: Phoenix Tissue Repair, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Redwood City, California • New York, New York

Conditions: Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
Interventions: Sirolimus, 2%, Vehicle; Drug
Lead sponsor: Stanford University; Other
Eligibility: 4 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Behcet Syndrome, Behcet Disease
Interventions: Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle); Drug
Lead sponsor: Silk Road Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hereditary Angioedema
Interventions: KVD900 600 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions: MAPLE; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Compassionate Use of Stanate (TM) [Stannsoporfin]

Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Evaluating the Effectiveness of a Chronic Disease Management Program for Gout

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic

Educational Needs of Patients With Systemic Vasculitis

Skin Tape Transcriptome Methods in Children

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

Topical Imiquimod Treatment of Oral Dysplasia

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

Study of an Intervention to Improve Problem List Accuracy and Use